Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11293927 Screening methods for PARP modulators

Patent 11293927 was granted and assigned to Ribon Therapeutics on April, 2022 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Patent Applicant

Ribon Therapeutics

Current Assignee

Ribon Therapeutics

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

112939270

Patent Inventor Names

Timothy J. N. Wigle0

Danielle J. Blackwell0

Kerren Kalai Swinger0

Kevin Wayne Kuntz0

Laurie B. Schenkel0

Melissa Marie Vasbinder0

Date of Patent

April 5, 2022

Patent Application Number

163974100

Date Filed

April 29, 2019

Patent Citations

‌

US Patent 10550105 Pyridazinones as PARP7 inhibitors

‌

US Patent 10870641 Pyridazinones as PARP7 inhibitors

‌

US Patent 11014913 Pyridazinones as PARP7 inhibitors

Patent Citations Received

‌

US Patent 11691969 Pyridazinones as PARP7 inhibtors

‌

US Patent 11566020 Pyridazinones as PARP7 inhibitors

Patent Primary Examiner

CPC Code

...

The present disclosure is related to methods of identifying Poly(ADP-ribose) polymerases (PARP) inhibitors, and the methods of using PARP probes.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11293927 Screening methods for PARP modulators

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API